Susan Moench, PhD, PA-C

This meta-analysis evaluated the effects of different therapeutic approaches on the live birth rate and maternal outcomes of pregnant women with MPNs.

Identifying progressive anemia and thrombocytopenia in patients with PV or ET may be predictive of MPN progression to secondary myelofibrosis.

A retrospective cohort study explored outcomes for pregnant women with HL who received antenatal chemotherapy compared with a match cohort of nonpregnant women.

No difference in event-free survival (EFS) was observed in children and adolescents with newly diagnosed Hodgkin lymphoma (HL) according to race/ethnicity; however, postrelapse mortality was found to be higher in nonwhite groups. The findings from this pooled, secondary analysis of data from phase 3 clinical trials of dose-dense, response-adapted therapy were published in the Journal…

Rates of grade 3/4 AEs and dose reductions/interruptions associated with CDK4/6 + AI therapy were higher in those 75 years and older compared with younger patients.

A case series study demonstrated the importance of timely, preventive dental assessment for patients with multiple myeloma.

This study sought to determine gender differences regarding melanoma survivors’ perceptions of partner support and comfort in performing skin self-examinations.

A call to action suggests cancer care should include interventions that help patients change how they think of their cancer and its treatment course.

An analysis of completion rates for PRO measures among patients with multiple myeloma found that reminders and use of preferred delivery mode influence response rate.

Described as “the fourth pillar” of cancer care, study findings demonstrate that a comprehensive tobacco treatment program can achieve long-term smoking cessation.